The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase

被引:22
作者
Engelbrecht, Idalet [1 ,2 ]
Petzer, Jacobus P. [1 ,2 ]
Petzer, Anel [2 ]
机构
[1] North West Univ, Sch Pharm, Pharmaceut Chem, ZA-2520 Potchefstroom, South Africa
[2] North West Univ, Ctr Excellence Pharmaceut Sci, ZA-2520 Potchefstroom, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Monoamine oxidase; MAO; Inhibition; Selective; Sesamol; Benzodioxane; PARKINSONS-DISEASE; SELEGILINE; LEVODOPA; TYRAMINE; THERAPY;
D O I
10.1016/j.bmcl.2015.03.040
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In the present study, series of eight sesamol (1,3-benzodioxol-5-ol) and eight benzodioxane (2,3-dihydro-1,4-benzodioxine) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The sesamol and benzodioxane derivatives are structurally related to series of phthalide derivatives, which have previously been found to act as potent reversible MAO inhibitors. The results document that the benzodioxane derivatives, in particular, are potent MAO-B inhibitors with IC50 values ranging from 0.045 to 0.947 mu M. IC50 values for the inhibition of MAO-B by the homologous series of sesamol derivatives ranged from 0.164 to 7.29 mu M. All compounds evaluated are selective for the MAO-B isoform, with IC50 values for the inhibition of MAO-A ranging from 13.2 to >100 mu M. It is further shown that for the most potent MAO-B inhibitor, 6-[(3-bromophenyl) methoxy]2,3- dihydro-1,4-benzodioxine, inhibition is almost completely reversed by dialysis of enzyme-inhibitor mixtures. It may be concluded that benzodioxane derivatives are promising leads for the design of selective MAO-B inhibitors for the treatment of Parkinson's disease. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1896 / 1900
页数:5
相关论文
共 28 条
  • [21] A neuroscientific update on monoamine oxidase and its inhibitors
    Schwartz, Thomas L.
    [J]. CNS SPECTRUMS, 2013, 18 : 22 - 33
  • [22] Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial
    Shoulson, I
    Oakes, D
    Fahn, S
    Lang, A
    Langston, JW
    LeWitt, P
    Olanow, CW
    Penney, JB
    Tanner, C
    Kieburtz, K
    Rudolph, A
    [J]. ANNALS OF NEUROLOGY, 2002, 51 (05) : 604 - 612
  • [23] Inhibition of monoamine oxidase by phthalide analogues
    Strydom, Belinda
    Bergh, Jacobus J.
    Petzer, Jacobus P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (05) : 1269 - 1273
  • [24] Inhibition of monoamine oxidase by 8-benzyloxycaffeine analogues
    Strydom, Belinda
    Malan, Sarel F.
    Castagnoli, Neal, Jr.
    Bergh, Jacobus J.
    Petzer, Jacobus P.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (03) : 1018 - 1028
  • [25] Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis
    Talati, R.
    Baker, W. L.
    Patel, A. A.
    Reinhart, K.
    Coleman, C. I.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 613 - 623
  • [26] The therapeutic potential of monoamine oxidase inhibitors
    Youdim, MBH
    Edmondson, D
    Tipton, KF
    [J]. NATURE REVIEWS NEUROSCIENCE, 2006, 7 (04) : 295 - 309
  • [27] Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness
    Youdim, MBH
    Bakhle, YS
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 147 : S287 - S296
  • [28] Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation
    Youdim, MBH
    Weinstock, M
    [J]. NEUROTOXICOLOGY, 2004, 25 (1-2) : 243 - 250